Commercial Insight: Parkinson's Disease - Increased Focus on Earlier Treatment and Managing Levodopa

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2004-08-30

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Despite the growth of generic levodopa products, Parkinson�s disease drug revenues grew an impressive 17% across the seven major markets to reach $1.7 billion in 2003, driven by the increasingly important role of the dopamine agonist class. However, several patent expiries and product launches are set to send the market through a period of change.


Scope

  • Overview of current market including profiles of key brands and key events impacting each brand during 2003-2004
  • Assessment of current and future opportunities and threats in the Parkinson�s disease market across the seven major pharmaceutical markets
  • Global sales for leading Parkinson�s disease from 1999-2003 are presented, with projections for future performance up to 2014
  • In-depth discussion of assumptions and events used in forecast analysis


    • Report Highlights
    Growing evidence for the role of the dopamine agonists as first-line therapy has ensured strong growth of this class, which now account for over half of the global market. However, with several generic dopamine agonists and novel drugs expected to launch over the next decade, current players must focus on new strategies, including reformulations.

    With a growth rate of 33.5% between 2002-03, the catechol-O-methyltransferase inhibitor class has witnessed the greatest year-on-year revenue growth, driven by Novartis�s Comtan and the company�s ability to position the drug as a treatment for niche patient cohorts. The recent launch of Stalevo will ensure the continued strong growth of this class.

    Marketed therapies work primarily to treat the symptoms of Parkinson�s disease. However, several compounds in development have demonstrated �neuroprotective� properties and have the potential to revolutionize the market. Nevertheless, reaching the market and providing convincing clinical evidence of this remains a huge challenge.


    Reasons to Purchase

  • Quantify future size and scope of Parkinson�s disease market and potential for new products
  • Understand key drivers to this market and predict future performance of these compounds
  • Identify future challenges for drug class and best method of meeting these

    • Table of Contents

    Other users found this report page using the following search terms: neuroprotection neurodegenerative parkinsons parkinsons disease market parkinson stalevo case patent study sales global

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.